HAIFA, Israel, March 23, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced that it has been granted a European Patent on its core 3D cell expansion technology. The granting of the European patent follows the issuance of several corresponding US patents as well as corresponding patents in ten additional jurisdictions. A divisional application of the now granted European application has been timely filed. In addition to these granted patents, Pluristem’s portfolio consists of 39 pending patent applications on the methods for production and expansion of stromal, progenitor and hematopoietic cells and the use of the obtained cells for the treatment of numerous severe degenerative, ischemic and autoimmune disorders in human subjects and for veterinary regenerative uses.
